[Long-term medical treatment of acute cerebrovascular disease sequelae (comparison papaverine-piribedil].
D002560:Cerebrovascular Circulation / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000150:complications* / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004149:Dioxoles / Q000627:therapeutic use; D004341:Drug Evaluation; D004361:Drug Tolerance; D001068:Feeding and Eating Disorders / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006261:Headache / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009120:Muscle Cramp / Q000188:drug therapy; D010208:Papaverine / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012893:Sleep Wake Disorders / Q000188:drug therapy; D013997:Time Factors; D014202:Tremor / Q000188:drug therapy; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014717:Vertigo / Q000188:drug therapy
D004149:Dioxoles; D010879:Piperazines; D011743:Pyrimidines; D014665:Vasodilator Agents; D010208:Papaverine
Trattamento medico a lungo termine dei postumi delle cerebrovasculopatie acute (confronto papaverina-piribedil)